S903
Clinical - Mixed sites & palliation
ESTRO 2026
Corradini 9 , Frances Duane 10 , Corinne Faivre-Finn 11 , Hossein Hemmatazad 12 , Orit Kaidar-Person 13 , Yolande Lievens 14 , Joseph Martin 15 , Icro Meattini 16 , Igor Sirak 17 , Pelagia Tsoutsou 18 , Felix Oppong 19 , Coreen Corning 19 , Enrico Clementel 19 , Nathalie Elaut 19 , Joachim Widder 20 , Jonas Willmann 1 , Marta Scorsetti 21,22 1 Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland. 2 Department of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Switzerland. 3 Department of Radiation Oncology, Iridium Netwerk, University of Antwerp, Health & Sciences, Antwerp, Belgium. 4 Division of Radiation Oncology, European Institute of Oncology, IRCCS, Milan, Italy. 5 Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia. 6 Department of Advanced Radiation Oncology, IRCCS Sacro Cuore Don Calabria, Negrar-Verona, Italy. 7 University of Brescia, University of Brescia, Brescia, Italy. 8 Department of Radiation Oncology, Hospital Universitari Vall d'Hebron -Vall d'Hebron Institut d’Oncologia, Barcelona, Spain. 9 Department of Radiation Oncology, LMU University Hospital, Munich, Germany. 10 St Luke's Radiation Oncology Network, Cancer Trials Ireland, Dublin, Ireland. 11 The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom. 12 Department of Radiation Oncology, Bern University Hospital , University of Bern, Bern, Switzerland. 13 Department of Radiation Oncology, Sheba Medical Center, Ramat Gan, Israel. 14 Department of Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium. 15 Department of Radiation Oncology,, University Hospital Galway, Galway, Ireland. 16 Department of Radiation Oncology, Univerity of Florence -Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 17 Department of Oncology and Radiotherapy, University Hospital Hradec Králové, Hradec Králové, Czech Republic. 18 Radiation Oncology Department, Geneva University Hospital, Geneva, Switzerland. 19 EORTC Headquarters, EORTC Headquarters, Brussels, Belgium. 20 Department of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. 21 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. 22 Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy Purpose/Objective: The ReCare cohort study is a pragmatic prospective observational cohort within the E2-RADIatE study (EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe). It aims to prospectively collect real word data
= 57), CNS (n = 3), and head and neck (n = 2). ReRT treatments most commonly addressed were local recurrences (34.2%), followed by metastases (24.5%), regional nodes (14.2%), non-regional nodes (7.1%), and new primaries (11.0%). Most treatments were with curative intent (68.6%), while local ablative or palliative intent were seen in 24.5% and 6.7%, respectively. Photon therapy was the predominant modality for both reirradiation (443/465, 95.3%) and prior radiotherapy (528/585, 90.3%), ranging 77.0–97.2% across disease types. Median prescription doses and number of fractions for reRT and prior RT are summarized in Table 1.In the matched subset of re- irradiated local recurrences with both prior and reRT plans available (n = 121), biologically equivalent doses (EQD2, Gy; reRT vs prior) were numerically lower during reRT for lung (59.8 vs 64.5), breast (46.0 vs 50.0), and prostate (71.4 vs 82.8), comparable for cervical (58.9 vs 58.9), and higher during reRT for colorectal (47.1 vs 44.3).Prior systemic therapy was reported in 219 patients (56.6%), most commonly hormonal (n = 120, 54.8%) and chemotherapy (n = 83, 37.9%). Concomitant systemic therapy during reRT was administered in 148 cases (38.2%), mainly hormonal (66.9%), chemotherapy (20.3%), targeted (14.2%), and immunotherapy (6.8%), varying by tumor type.
Conclusion: The ReCare cohort provides a comprehensive prospective overview of site-specific reRT practices. Substantial heterogeneity in treatment intent, dose, and systemic treatment integration highlights the need for further analyses to improve the evidence-
base for this emerging treatment setting. Keywords: reirradiation, prospective, dose
Proffered Paper 3692
Interim analysis of the EORTC ESTRO ReCare to assess adequacy of patient selection: Early death and adverse events after high-dose re-irradiation Nicolaus Andratschke Andratschke 1 , Vincent Dick 2 , Melanie Machiels 3 , Barbara Jereczek-Fossa 4 , Sta š a Jeler č i č 5 , Filippo Alongi 6,7 , Sergi Benavente 8 , Stefanie
Made with FlippingBook - Share PDF online